{"id":2070,"date":"2019-11-22T12:49:33","date_gmt":"2019-11-22T11:49:33","guid":{"rendered":"https:\/\/www.maiwald.eu\/all\/presseberichte\/royalty-pharma-announces-100-million-acquisition-of-royalty-rights-in-cardiovascular-drug-omecamtiv-mecarbil-from-cytokinetics-royalty-pharma\/"},"modified":"2021-10-06T18:03:39","modified_gmt":"2021-10-06T16:03:39","slug":"royalty-pharma-announces-100-million-acquisition-of-royalty-rights-in-cardiovascular-drug-omecamtiv","status":"publish","type":"presseberichte","link":"https:\/\/www.maiwald.eu\/jp\/press-coverage\/royalty-pharma-announces-100-million-acquisition-of-royalty-rights-in-cardiovascular-drug-omecamtiv\/","title":{"rendered":"Royalty Pharma Announces $100 million Acquisition of Royalty Rights in cardiovascular drug Omecamtiv Mecarbil from Cytokinetics (Royalty Pharma)"},"content":{"rendered":"\n<p><em>Royalty Pharma Buys 4.5 Percent Royalty on Worldwide Sales for $90 Million Plus $10 Million Equity in Cytokinetics.<\/em><\/p>\n\n\n\n<p><em>Cytokinetics Agrees to Exercise Option to Co-Fund Phase 3 Development Program Under Collaboration with Amgen for Increased Royalty and Co-Promotion Rights in North America.<\/em><\/p>\n\n\n\n<p>Royalty Pharma and Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Cytokinetics has agreed to sell to Royalty Pharma a portion of the potential royalty due to Cytokinetics from Amgen on worldwide sales of omecamtiv mecarbil. Cytokinetics has also agreed to exercise its option to co-invest with Amgen in the Phase 3 development program of omecamtiv mecarbil in exchange for increased royalties from Amgen on worldwide sales of omecamtiv mecarbil outside Japan and co-promotion rights.<\/p>\n\n\n\n<p>Cytokinetics sold to Royalty Pharma a 4.5 percent royalty on potential worldwide sales of omecamtiv mecarbil for $90 million in an upfront cash payment. The royalty rate purchased may increase up to an additional 1 percent under certain circumstances. In addition, Royalty Pharma has agreed to purchase $10 million of Cytokinetics\u2019 common stock.<\/p>\n\n\n\n<p>Cytokinetics has also agreed with Royalty Pharma to exercise its option to co-invest $40 million in the Phase 3 development program of omecamtiv mecarbil under its collaboration with Amgen. As a result, Cytokinetics is eligible to receive an incremental royalty of up to 4 percent on increasing worldwide sales of omecamtiv mecarbil outside of Japan. Following the transaction with Royalty Pharma, Cytokinetics retains the right to receive more than $600 million in potential milestone payments as well as escalating double-digit royalties that may exceed 20 percent on tiered worldwide sales of omecamtiv mecarbil outside Japan, with a lower royalty rate in Japan under the Amgen Agreement.<\/p>\n\n\n\n<p>Exercising its option and co-funding will afford Cytokinetics the right to co-promote omecamtiv mecarbil in institutional care settings in North America, with reimbursement by Amgen for certain sales force activities. A joint commercial operating team comprising representatives of Cytokinetics and Amgen will then be responsible for the commercialization program of omecamtiv mecarbil.<\/p>\n\n\n\n<p>[&#8230;]<\/p>\n\n\n\n<p>Centerview Partners LLC acted as financial advisor to Cytokinetics on the transaction. Cooley LLP and Morrison &amp; Foerster acted as legal advisors to Cytokinetics on the transaction. Goodwin, Wolf Greenfield, and Maiwald acted as legal advisors to Royalty Pharma on the transaction.<\/p>\n\n\n\n<p>This text is a press release from Royalty Pharma. The full text version of the article can be found here: <a href=\"https:\/\/www.royaltypharma.com\/royalty-pharma-and-cytokinetics-omecamtive-mecarbil\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.royaltypharma.com\/royalty-pharma-and-cytokinetics-omecamtive-mecarbil\/<\/a><\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-2070","presseberichte","type-presseberichte","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/presseberichte\/2070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/presseberichte"}],"about":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/types\/presseberichte"}],"version-history":[{"count":1,"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/presseberichte\/2070\/revisions"}],"predecessor-version":[{"id":9584,"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/presseberichte\/2070\/revisions\/9584"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/media?parent=2070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}